A detailed history of Royal Bank Of Canada transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 2,790 shares of VRCA stock, worth $22,180. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,790
Previous 2,481 12.45%
Holding current value
$22,180
Previous $14,000 42.86%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.89 - $9.56 $1,820 - $2,954
309 Added 12.45%
2,790 $20,000
Q1 2024

May 15, 2024

SELL
$4.74 - $6.81 $29,771 - $42,773
-6,281 Reduced 71.68%
2,481 $14,000
Q4 2023

Feb 14, 2024

SELL
$2.93 - $7.32 $2,279 - $5,694
-778 Reduced 8.16%
8,762 $64,000
Q3 2023

Nov 14, 2023

SELL
$3.75 - $7.46 $641 - $1,275
-171 Reduced 1.76%
9,540 $37,000
Q2 2023

Aug 14, 2023

BUY
$5.32 - $6.79 $29,121 - $37,168
5,474 Added 129.2%
9,711 $56,000
Q1 2023

May 15, 2023

BUY
$2.88 - $8.51 $4,003 - $11,828
1,390 Added 48.82%
4,237 $27,000
Q4 2022

Feb 14, 2023

BUY
$2.09 - $3.39 $12 - $20
6 Added 0.21%
2,847 $7,000
Q3 2022

Nov 14, 2022

SELL
$2.17 - $4.3 $651,000 - $1.29 Million
-300,000 Reduced 99.06%
2,841 $8,000
Q2 2022

Aug 15, 2022

BUY
$1.81 - $8.93 $542,357 - $2.68 Million
299,645 Added 9375.63%
302,841 $581,000
Q1 2022

May 16, 2022

SELL
$7.59 - $9.49 $16,644 - $20,811
-2,193 Reduced 40.69%
3,196 $26,000
Q4 2021

Feb 14, 2022

BUY
$9.1 - $13.36 $24,315 - $35,697
2,672 Added 98.34%
5,389 $49,000
Q3 2021

Nov 15, 2021

BUY
$9.55 - $13.96 $7,172 - $10,483
751 Added 38.2%
2,717 $35,000
Q2 2021

Aug 16, 2021

BUY
$9.77 - $15.33 $19,207 - $30,138
1,966 New
1,966 $22,000

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.